Ojjaara
GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia
September 18, 2023Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
